HOX Gene Expression Predicts Response to BCL-2 Inhibition in Acute Myeloid Leukemia

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2016 Aug 9

PMID 27499136

Citations 48

Authors

M Kontro

A Kumar

M M Majumder

S Eldfors

A Parsons

T Pemovska

J Saarela

B Yadav

D Malani

Y Floisand

M Hoglund

K Remes

B T Gjertsen

O Kallioniemi

K Wennerberg

C A Heckman

K Porkka

Affiliations

Soon will be listed here.

Abstract

Inhibitors of B-cell lymphoma-2 (BCL-2) such as venetoclax (ABT-199) and navitoclax (ABT-263) are clinically explored in several cancer types, including acute myeloid leukemia (AML), to selectively induce apoptosis in cancer cells. To identify robust biomarkers for BCL-2 inhibitor sensitivity, we evaluated the ex vivo sensitivity of fresh leukemic cells from 73 diagnosed and relapsed/refractory AML patients, and then comprehensively assessed whether the responses correlated to specific mutations or gene expression signatures. Compared with samples from healthy donor controls (nonsensitive) and chronic lymphocytic leukemia (CLL) patients (highly sensitive), AML samples exhibited variable responses to BCL-2 inhibition. Strongest CLL-like responses were observed in 15% of the AML patient samples, whereas 32% were resistant, and the remaining exhibited intermediate responses to venetoclax. BCL-2 inhibitor sensitivity was associated with genetic aberrations in chromatin modifiers, WT1 and IDH1/IDH2. A striking selective overexpression of specific HOXA and HOXB gene transcripts were detected in highly BCL-2 inhibitor sensitive samples. Ex vivo responses to venetoclax showed significant inverse correlation to β2-microglobulin expression and to a lesser degree to BCL-XL and BAX expression. As new therapy options for AML are urgently needed, the specific HOX gene expression pattern can potentially be used as a biomarker to identify venetoclax-sensitive AML patients for clinical trials.

Citing Articles

Identification of senescence-related genes for potential therapeutic biomarkers of atrial fibrillation by bioinformatics, human histological validation, and molecular docking.

Liu J, Zhou T, Bao Y, Lin C, Chen Q, Dai Y Heliyon. 2024; 10(19):e37366.

PMID: 39381104 PMC: 11456832. DOI: 10.1016/j.heliyon.2024.e37366.

NUP98 oncofusions in myeloid malignancies: An update on molecular mechanisms and therapeutic opportunities.

Rasouli M, Troester S, Grebien F, Goemans B, Zwaan C, Heidenreich O Hemasphere. 2024; 8(9):e70013.

PMID: 39323480 PMC: 11423334. DOI: 10.1002/hem3.70013.

Aberrant HIF1- α and SIX-1 Expression is Associated with Poor Prognosis in Acute Myeloid Leukemia Patients with Isocitrate Dehydrogenase 1 Mutations.

Ali T, Usman R, Shah S, Parvez A, Anwar S, Muneer Z Cancer Control. 2024; 31:10732748241271714.

PMID: 39110525 PMC: 11307363. DOI: 10.1177/10732748241271714.

Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies?.

Masetti R, Baccelli F, Leardini D, Locatelli F Blood Adv. 2024; 8(13):3583-3595.

PMID: 38701350 PMC: 11319833. DOI: 10.1182/bloodadvances.2023012041.

Regulation of HOX gene expression in AML.

Khan I, Amin M, Eklund E, Gartel A Blood Cancer J. 2024; 14(1):42.

PMID: 38453907 PMC: 10920644. DOI: 10.1038/s41408-024-01004-y.

References

Nomura T, Huang W, Zhau H, Wu D, Xie Z, Mimata H . Beta2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis. Clin Cancer Res. 2006; 12(24):7294-305. DOI: 10.1158/1078-0432.CCR-06-2060. View

Roberts A, Davids M, Pagel J, Kahl B, Puvvada S, Gerecitano J . Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 374(4):311-22. PMC: 7107002. DOI: 10.1056/NEJMoa1513257. View

Souers A, Leverson J, Boghaert E, Ackler S, Catron N, Chen J . ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19(2):202-8. DOI: 10.1038/nm.3048. View

Dohner H, Weisdorf D, Bloomfield C . Acute Myeloid Leukemia. N Engl J Med. 2015; 373(12):1136-52. DOI: 10.1056/NEJMra1406184. View

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View

Wong T, Ramsingh G, Young A, Miller C, Touma W, Welch J . Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2014; 518(7540):552-555. PMC: 4403236. DOI: 10.1038/nature13968. View

Nomura T, Huang W, Zhau H, Josson S, Mimata H, Chung L . β2-Microglobulin-mediated signaling as a target for cancer therapy. Anticancer Agents Med Chem. 2013; 14(3):343-52. PMC: 3931390. DOI: 10.2174/18715206113139990092. View

Benito J, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H . MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Rep. 2015; 13(12):2715-27. PMC: 4700051. DOI: 10.1016/j.celrep.2015.12.003. View

Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R . Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Rep. 2014; 4:5193. PMC: 4046135. DOI: 10.1038/srep05193. View

10.

Shi C, Zhu Y, Su Y, Chung L, Cheng T . Beta2-microglobulin: emerging as a promising cancer therapeutic target. Drug Discov Today. 2008; 14(1-2):25-30. DOI: 10.1016/j.drudis.2008.11.001. View

11.

Tse C, Shoemaker A, Adickes J, Anderson M, Chen J, Jin S . ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008; 68(9):3421-8. DOI: 10.1158/0008-5472.CAN-07-5836. View

12.

Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A . Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013; 3(12):1416-29. DOI: 10.1158/2159-8290.CD-13-0350. View

13.

Koboldt D, Zhang Q, Larson D, Shen D, McLellan M, Lin L . VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012; 22(3):568-76. PMC: 3290792. DOI: 10.1101/gr.129684.111. View

14.

Rampal R, Alkalin A, Madzo J, Vasanthakumar A, Pronier E, Patel J . DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 2014; 9(5):1841-1855. PMC: 4267494. DOI: 10.1016/j.celrep.2014.11.004. View

15.

Koskela H, Eldfors S, Ellonen P, van Adrichem A, Kuusanmaki H, Andersson E . Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012; 366(20):1905-13. PMC: 3693860. DOI: 10.1056/NEJMoa1114885. View

16.

Gordon J, Wu C, Rastegar M, Safa A . Beta2-microglobulin induces caspase-dependent apoptosis in the CCRF-HSB-2 human leukemia cell line independently of the caspase-3, -8 and -9 pathways but through increased reactive oxygen species. Int J Cancer. 2002; 103(3):316-27. DOI: 10.1002/ijc.10828. View

17.

Anderson M, Huang D, Roberts A . Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol. 2014; 51(3):219-27. DOI: 10.1053/j.seminhematol.2014.05.008. View

18.

Dohner H, Estey E, Amadori S, Appelbaum F, Buchner T, Burnett A . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2009; 115(3):453-74. DOI: 10.1182/blood-2009-07-235358. View

19.

Giampaolo A, Sterpetti P, Bulgarini D, Samoggia P, Pelosi E, Valtieri M . Key functional role and lineage-specific expression of selected HOXB genes in purified hematopoietic progenitor differentiation. Blood. 1994; 84(11):3637-47. View

20.

Niu X, Wang G, Wang Y, Caldwell J, Edwards H, Xie C . Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. Leukemia. 2014; 28(7):1557-60. PMC: 4090260. DOI: 10.1038/leu.2014.72. View